Nurix Therapeutics Stock Rises on Positive Trial Data for Blood Cancer Treatment

Dow Jones12-08 22:48

By Kelly Cloonan

Shares of Nurix Therapeutics rose after the company reported positive trial data for a potential treatment for a type of blood cancer.

The stock rose 22% to $22.01 on Monday. Shares are up 13% this year.

The biopharmaceutical company said its Bexobrutideg showed an objective response rate of 75%, including three very good partial responses, in heavily pre-treated Waldenström macroglobulinemia patients in a recent trial.

The data demonstrates durable and deepening responses with longer time on treatment, and shows that the drug was well tolerated, consistent with previous disclosures, Chief Medical Officer Paula O'Connor said.

The drug's encouraging efficacy and favorable tolerability support continued development, the company said.

Waldenström macroglobulinemia is a rare cancer that affects white blood cells.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

December 08, 2025 09:48 ET (14:48 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589351532?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 22:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589351532","market":"hk","top_or_hot":-1,"title":"Nurix Therapeutics Stock Rises on Positive Trial Data for Blood Cancer Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> rose after the company reported positive trial data for a potential treatment for a type of blood cancer. \n</p>\n<p>\n  The stock rose 22% to $22.01 on Monday. Shares are up 13% this year. \n</p>\n<p>\n  The biopharmaceutical company said its Bexobrutideg showed an objective response rate of 75%, including three very good partial responses, in heavily pre-treated Waldenström macroglobulinemia patients in a recent trial. \n</p>\n<p>\n  The data demonstrates durable and deepening responses with longer time on treatment, and shows that the drug was well tolerated, consistent with previous disclosures, Chief Medical Officer Paula O'Connor said. \n</p>\n<p>\n  The drug's encouraging efficacy and favorable tolerability support continued development, the company said. \n</p>\n<p>\n  Waldenström macroglobulinemia is a rare cancer that affects white blood cells. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 08, 2025 09:48 ET (14:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nurix Therapeutics Stock Rises on Positive Trial Data for Blood Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNurix Therapeutics Stock Rises on Positive Trial Data for Blood Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-08 22:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> rose after the company reported positive trial data for a potential treatment for a type of blood cancer. \n</p>\n<p>\n  The stock rose 22% to $22.01 on Monday. Shares are up 13% this year. \n</p>\n<p>\n  The biopharmaceutical company said its Bexobrutideg showed an objective response rate of 75%, including three very good partial responses, in heavily pre-treated Waldenström macroglobulinemia patients in a recent trial. \n</p>\n<p>\n  The data demonstrates durable and deepening responses with longer time on treatment, and shows that the drug was well tolerated, consistent with previous disclosures, Chief Medical Officer Paula O'Connor said. \n</p>\n<p>\n  The drug's encouraging efficacy and favorable tolerability support continued development, the company said. \n</p>\n<p>\n  Waldenström macroglobulinemia is a rare cancer that affects white blood cells. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 08, 2025 09:48 ET (14:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2589351532","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589351532","pubTimestamp":1765205280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Nurix Therapeutics rose after the company reported positive trial data for a potential treatment for a type of blood cancer.The stock rose 22% to $22.01 on Monday. Shares are up 13% this year.The biopharmaceutical company said its Bexobrutideg showed an objective response rate of 75%, including three very good partial responses, in heavily pre-treated Waldenstrm macroglobulinemia patients in a recent trial.The data demonstrates durable and deepening responses with longer time on treatment, and shows that the drug was well tolerated, consistent with previous disclosures, Chief Medical Officer Paula O'Connor said.The drug's encouraging efficacy and favorable tolerability support continued development, the company said.Waldenstrm macroglobulinemia is a rare cancer that affects white blood cells.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NRIX":"Nurix Therapeutics"},"translate_title":"Nurix Therapeutics股价因血癌治疗试验数据积极而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRIX":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Nurix Therapeutics rose after the company reported positive trial data for a potential treatment for a type of blood cancer. \n\n\n  The stock rose 22% to $22.01 on Monday. Shares are up 13% this year. \n\n\n  The biopharmaceutical company said its Bexobrutideg showed an objective response rate of 75%, including three very good partial responses, in heavily pre-treated Waldenström macroglobulinemia patients in a recent trial. \n\n\n  The data demonstrates durable and deepening responses with longer time on treatment, and shows that the drug was well tolerated, consistent with previous disclosures, Chief Medical Officer Paula O'Connor said. \n\n\n  The drug's encouraging efficacy and favorable tolerability support continued development, the company said. \n\n\n  Waldenström macroglobulinemia is a rare cancer that affects white blood cells. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 09:48 ET (14:48 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589351532","isCrawlerRequest":true}